Xsphera Biosciences Inc

Excited to present new cell therapy data from our lab at the upcoming Next-Gen Immuno-Oncology Conference in Boston, June 20-21. I will be sharing unpublished findings that show candidate selection profiling in a new translational research platform that leverages human tumor tissue, endogenous immune cells and microfluidics. We have been able to link these data together with patient stratification to potentially predict responsive patient populations in later phase trials. The work I'll present is in collaboration with our industry partner, Xsphera Biosciences Inc. An exciting partnership that has been transformative for studying cell therapy activity! Would be great to see my network there! Thanks to the organizers and Shagun Kochhar for giving me the opportunity to share these new data. https://lnkd.in/dmSTkRhe

Dr. Aaron Goldman, Faculty and Instructor in Medicine at Harvard Medical School and Process Advisor at Xsphera Biosciences, will be presenting at the Next-Gen Immuno-Oncology Conference. Join us on June 20th for his insightful session on "Next Generation Translational Research Platforms for Cell Therapy in Cancer." https://lnkd.in/dNiS8jhR Don't miss this opportunity to learn about the innovative XspheraCT technology. Mark your calendars! #Celltherapy #oncology #immunooncology #cancer #translationalresearch #PDOTS #preclinical

Heading to Bio2024 in San Diego? Don’t miss the chance to connect with Kazu Ishikawa, our VP of Business Development! This event is a fantastic opportunity to discover how our platform can revolutionize preclinical testing. We’re eager to discuss potential collaborations to advance your oncology drug development. Reach out through the partnering system or directly at kazu@xspherabio.com. Let’s make progress together! #BIO2024 #xsphera #drugdiscovery #PDOTS ##tumormicroenvironment #spheroids #preclinical #oncology #immuneoncology #cancer

Cell therapy translational research platforms are limited. Xsphera Biosciences is excited to introduce XspheraCT, a purpose built translational research program that leverages the microfluidics, human tissue platform for cell therapy developers. Using a diversity of in-house tools and fresh human tissue, XspheraCT allows developers of cancer cell therapy to better elucidate lead optimization, candidate profiling and patient stratification. To demonstrate the power of XspheraCT, our team has created a white paper that describes the necessity for more advanced approaches in cell therapy translational research. We also demonstrate our proof of concept and published, peer-reviewed evidences in human tumor samples. Click the link below to access the white paper, peruse our website offerings and reach out to the team at sales@xspherabio.com. https://lnkd.in/gbHCAdnW We look forward to helping you develop your cell therapy program! #celltherapy #oncology #cancer #PDOTS #TME #tumormicroenvironment #immunooncology #solidtumor

If you're attending BioKorea in Seoul this May, I invite you to connect with Kazu Ishikawa, our Vice President of Business Development. This event presents a valuable opportunity to explore how our platform can overcome the limitations of current preclinical testing. We are eager to schedule an introductory meeting to discuss potential collaborations that could enhance your oncology drug development initiatives. Please feel free to reach out through the partnering system or directly via email at kazu@xspherabio.com. #biokorea2024 #biokorea #xsphera #drugdiscovery #PDOTS ##tumormicroenvironment #spheroids #preclinical #oncology #immuneoncology #cancer

We are excited to share the poster on the collaborative study with NomoCan Pharmaceuticals at the AACR 2024 in San Diego. "Advanced Ex Vivo Platform for Target Expression and Drug Response Analysis: Evaluating the Potent Effects of NMC-521 mAb on Fresh Mouse- and Patient-Derived Organotypic Tumor Spheroids" Efficacy was shown with CT26 MDOTS (Mouse-Derived Organotypic Tumor Spheroids), which mirrored in-vivo CT26 mouse model. PDOTS ( Patient-Derived Organotypic Tumor Spheroids ) confirmed cytotoxic effects in some patient tumors were elicited Our study highlights their roles in demonstrating drug efficacy and mechanism of action (MoA). https://lnkd.in/g8gSyhRF #AACR #AACR2024 #PDOTS #MDOTS #geneexpression #Immunecontexture #solidtumors #immuneoncology #oncology #cancer #tumormicroenvironment #spheroids

We invite you to visit our poster on the collaborative study with Nomocan Pharmaceuticals at the AACR 2024 in San Diego. Learn about the advantages of MDOTS (Mouse-Derived Organotypic Tumor Spheroids) and PDOTS ( Patient-Derived Organotypic Tumor Spheroids ) in advancing drug development. Our study highlights their roles in demonstrating drug efficacy and mechanism of action (MoA). The poster will be on April 8 from 1:30 AM to 5:00 PM. Michael Perricone will be available at the conference venue to connect with attendees interested in learning more about our platform. Advanced ex vivo platform for drug response analysis: Evaluating the potent effects of NMC-521 mAb on mouse-and patient-derived organotypic tumor spheroids #AACR #AACR2024 #PDOTS #MDOTS #geneexpression #Immunecontexture #solidtumors #oncology #cancer #tumormicroenvironment #spheroids #NSCLC

At AACR 2024, you will find many studies using patient-derived organotypic tumor spheroids (PDOTS). Learn how PDOTS is enhancing our approach to cancer research through in-depth research and novel methodologies.   🔬 Highlighted Sessions:   📅 Date: April 8 ⏰ Time: 1:30 PM - 5:00 PM 📍 Location: Section 54 Advanced ex vivo platform for drug response analysis: Evaluating the potent effects of NMC-521 mAb on mouse-and patient-derived organotypic tumor spheroids   📅 Date: April 9 ⏰ Time: 9:00 AM – 12:30 PM 📍 Location: Section 2 TBK1 inhibition enhances CAR-T cell efficacy against patient-derived organotypic tumor spheroids   📅 Date: April 9 ⏰ Time: 9:00 AM - 12:30 PM 📍 Location: Section 11 Evaluation of NXI-101 in non-small cell lung cancer (NSCLC) using patient-derived organotypic tumor spheroids (PDOTS): Targeting a novel tumorigenic pathway   📅 Date: April 9 ⏰ Time: 9:00 AM – 12:30 PM 📍 Location: Section 42 Functional profiling in lung tumor explants show contributions of the tumor microenvironment to response of Dato-DXdex vivo   📅 Date: April 9 ⏰ Time: 1:30 PM – 5:00 PM 📍 Location: Section 1 Combination STING agonist and NK cellular therapy in patient derived organotypic tumor spheroids   📅 Date: April 10 ⏰ Time: 9:00 AM – 12:30 PM 📍 Location: Section 4 Multiomics analysis of impact of CD8+ and other cell populations in STING agonist treated ex vivo mesothelioma samples   #AACR #AACR2024 #CancerResearch #PDOTS #Oncology #Innovation #Solidrumors #Cancer #tumormicroenvironment #spheroids

Please stop by our poster if you attend AACR 2024 in San Diego. This is a great collaboration with NEX-I. The poster will be on April 9 from 9:00 AM to 12:30 PM. Michael Perricone will be available at the conference venue to connect with attendees interested in learning more about our platform. Title: Evaluation of NXI-101 in non-small cell lung cancer (NSCLC) using patient-derived organotypic tumor spheroids (PDOTS): Targeting a novel tumorigenic pathway #AACR #AACR2024 #PDOTS #geneexpression #Immunecontexture #solidtumors #oncology #cancer #tumormicroenvironment #antibody #spheroids #NSCLC

I am looking forward connecting with my colleagues at AACR. Here is another published abstract and example of a successful SRA. If you want PDOTS you want to work with the best. Collective evidence highlights that agonism of the host STING pathway plays a critical role in eliciting robust and durable anti-tumor immunity. Dazostinag is a novel systemically delivered STING agonist that ignites the innate immune system and mobilizes adaptive immunity. Preclinical studies with dazostinag demonstrated a strong, persistent CD8+ T cell anti-tumor response driven by innate immune derived type I IFN and pro-inflammatory cytokines. The role of CD8+ T cells in response to dazostinag was further supported by a previously demonstrated correlation between response and CD8+ T cell frequency in a patient-derived organotypic tumor spheroids of mesothelioma. Within the current work, we sought to determine the extent to which response to dazostinag in mesothelioma depends on CD8+ T cells versus the contribution of other immune cells. Surgical mesothelioma cases were collected along with clinicopathological variables at Brigham and Women’s Hospital under an IRB-approved protocol. PDOTS were generated as described previously. Ex vivo response was determined by fluorescent life/dead imaging, and orthogonally evaluated by multiplexed cytokine array, immunofluorescence, and flow cytometry; subset of tumors was studied using scRNAseq. Dazostinag-driven tumor cell killing was evaluated in 20 mesothelioma PDOTS. 11 samples were characterized as responders (R) with a cut-off of >30% reduction in live cell area; 9 as non-responders (NR). In 12 out of 20 PDOTS, CD8 neutralization effect was assessed: four were TAK-676 NR, and out of 8 R 4 had at least 20% killing abrogated by aCD8. Effect did not depend on the baseline amount of CD8+ T cells in the sample. scRNAseq analysis showed that R and NR T cells have different activation/exhaustion phenotypes and varying levels of interferon stimulated genes in response to STING agonism. Other cell populations emerged as candidates for dazostinag resistance: NR cases carried remodeled immunosuppressive myeloid cells or matrix metalloproteinases-expressing fibroblasts. In general, myeloid cell abundance at baseline characterized by flow had a trend in negatively correlating with dazostinag response. Intrinsic expression of type I interferons shown by multiplexed cytokine array was linked to dazostinag sensitivity (R vs. NR IFN-β p=0.028; IFNα2a p=0.016) and can potentially be used as a predictor for response. We evaluated immune modulations in mesothelioma after treatment with a systemic STING agonist dazostinag using human tumor ex vivo culture. Innate interferon type I expression was higher in responding samples. TAK-676 efficacy was partially reduced in absence of effector lymphocytes, however other cells, such as immunosuppressive myeloid cells and fibroblasts, can have a negative impact on dazostinag response in mesothelioma.